TRUST THE EYLEA EXPERIENCE

EYLEA 2 mg is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).^[1]

The tried-and-trusted EYLEA molecule is supported by extensive evidence in both pivotal trials and clinical practice.

^[1][2]

Prescribing information for EYLEA® (aflibercept) 8 mg can be found here.

Abbreviations

DMO, diabetic macular oedema. mCNV, myopic choroidal neovascularisation. MoA, mechanism of action. nAMD, neovascular age-related macular degeneration. R&D, research and development. RVO, retinal vein occlusion. VEGF, vascular endothelial growth factor.